SEC Form IRANNOTICE filed by Qiagen N.V.
$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
March 19, 2026
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Notice of Disclosure Filed in Exchange Act Annual Report Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that QIAGEN N.V. has made disclosure pursuant to such provisions in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission on March 19, 2026.
Sincerely,
| /s/ Roland Sackers | ||
Roland Sackers | ||
Chief Financial Officer | ||